4.5 Article

[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Oncology

Outcomes and endpoints in cancer trials: bridging the divide

Michelle K. Wilson et al.

LANCET ONCOLOGY (2015)

Article Radiology, Nuclear Medicine & Medical Imaging

Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options

Antonio José Conde Moreno et al.

Radiation Oncology (2014)

Article Oncology

Stereotactic Body Radiotherapy in the Treatment of Adrenal Metastases

Kamran A. Ahmed et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)

Article Oncology

Cancer statistics, 2013

Rebecca Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2013)

Review Oncology

Stereotactic body radiotherapy for oligometastases

Alison C. Tree et al.

LANCET ONCOLOGY (2013)

Article Radiology, Nuclear Medicine & Medical Imaging

Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy

Chiara Fuccio et al.

EUROPEAN JOURNAL OF RADIOLOGY (2012)

Article Oncology

Global Cancer Statistics

Ahmedin Jemal et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2011)

Article Oncology

PREDICTORS OF LOCAL CONTROL AFTER SINGLE-DOSE STEREOTACTIC IMAGE-GUIDED INTENSITY-MODULATED RADIOTHERAPY FOR EXTRACRANIAL METASTASES

Carlo Greco et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)

Article Radiology, Nuclear Medicine & Medical Imaging

Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy

Giampiero Giovacchini et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)

Article Radiology, Nuclear Medicine & Medical Imaging

Stereotactic body radiation therapy: The report of AAPM Task Group 101

Stanley H. Benedict et al.

MEDICAL PHYSICS (2010)

Article Medicine, General & Internal

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

IF Tannock et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)